S&P 500   4,296.52 (+0.20%)
DOW   33,481.94 (-0.08%)
QQQ   361.65 (+0.94%)
AAPL   173.89 (+1.57%)
MSFT   320.25 (+1.43%)
META   306.10 (+1.96%)
GOOGL   133.93 (+2.35%)
AMZN   129.91 (+2.19%)
TSLA   252.34 (+0.85%)
NVDA   450.52 (+3.57%)
NIO   8.83 (-2.32%)
BABA   86.29 (-0.52%)
AMD   102.95 (+0.13%)
T   14.86 (-1.07%)
F   12.30 (-0.97%)
MU   68.09 (+0.09%)
CGC   0.79 (+1.32%)
GE   109.46 (-0.99%)
DIS   81.12 (+0.09%)
AMC   7.92 (-0.88%)
PFE   33.40 (+0.69%)
PYPL   58.96 (+0.86%)
NFLX   382.08 (+1.19%)
S&P 500   4,296.52 (+0.20%)
DOW   33,481.94 (-0.08%)
QQQ   361.65 (+0.94%)
AAPL   173.89 (+1.57%)
MSFT   320.25 (+1.43%)
META   306.10 (+1.96%)
GOOGL   133.93 (+2.35%)
AMZN   129.91 (+2.19%)
TSLA   252.34 (+0.85%)
NVDA   450.52 (+3.57%)
NIO   8.83 (-2.32%)
BABA   86.29 (-0.52%)
AMD   102.95 (+0.13%)
T   14.86 (-1.07%)
F   12.30 (-0.97%)
MU   68.09 (+0.09%)
CGC   0.79 (+1.32%)
GE   109.46 (-0.99%)
DIS   81.12 (+0.09%)
AMC   7.92 (-0.88%)
PFE   33.40 (+0.69%)
PYPL   58.96 (+0.86%)
NFLX   382.08 (+1.19%)
S&P 500   4,296.52 (+0.20%)
DOW   33,481.94 (-0.08%)
QQQ   361.65 (+0.94%)
AAPL   173.89 (+1.57%)
MSFT   320.25 (+1.43%)
META   306.10 (+1.96%)
GOOGL   133.93 (+2.35%)
AMZN   129.91 (+2.19%)
TSLA   252.34 (+0.85%)
NVDA   450.52 (+3.57%)
NIO   8.83 (-2.32%)
BABA   86.29 (-0.52%)
AMD   102.95 (+0.13%)
T   14.86 (-1.07%)
F   12.30 (-0.97%)
MU   68.09 (+0.09%)
CGC   0.79 (+1.32%)
GE   109.46 (-0.99%)
DIS   81.12 (+0.09%)
AMC   7.92 (-0.88%)
PFE   33.40 (+0.69%)
PYPL   58.96 (+0.86%)
NFLX   382.08 (+1.19%)
S&P 500   4,296.52 (+0.20%)
DOW   33,481.94 (-0.08%)
QQQ   361.65 (+0.94%)
AAPL   173.89 (+1.57%)
MSFT   320.25 (+1.43%)
META   306.10 (+1.96%)
GOOGL   133.93 (+2.35%)
AMZN   129.91 (+2.19%)
TSLA   252.34 (+0.85%)
NVDA   450.52 (+3.57%)
NIO   8.83 (-2.32%)
BABA   86.29 (-0.52%)
AMD   102.95 (+0.13%)
T   14.86 (-1.07%)
F   12.30 (-0.97%)
MU   68.09 (+0.09%)
CGC   0.79 (+1.32%)
GE   109.46 (-0.99%)
DIS   81.12 (+0.09%)
AMC   7.92 (-0.88%)
PFE   33.40 (+0.69%)
PYPL   58.96 (+0.86%)
NFLX   382.08 (+1.19%)
Lowest-Rated StocksLowest-RatedMost-Downgraded StocksMost-Downgraded
NASDAQ:PTCT

PTC Therapeutics (PTCT) Stock Forecast, Price & News

$21.89
-0.52 (-2.32%)
(As of 11:15 AM ET)
Compare
Today's Range
$21.69
▼
$22.31
50-Day Range
$22.41
▼
$41.80
52-Week Range
$21.69
▼
$59.84
Volume
147,464 shs
Average Volume
835,826 shs
Market Capitalization
$1.65 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.57
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

PTC Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
76.6% Upside
$39.57 Price Target
Short Interest
Bearish
9.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
0.29mentions of PTC Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$465,007 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.46) to ($4.36) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

343rd out of 968 stocks

Pharmaceutical Preparations Industry

142nd out of 453 stocks

See Top Rated MarketRank™ Stocks Here

PTCT stock logo

About PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT Price History

PTCT Stock News Headlines

September 30, 2023 | markets.businessinsider.com
PTC Therapeutics Cuts 25% Of Jobs; To Submit Re-examination Request For CHMP Opinion On Translarna
September 29, 2023 | finance.yahoo.com
PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
September 29, 2023 | markets.businessinsider.com
PTC Therapeutics’ Restructuring and Reapplication Strategies Bolster Buy Rating: An Analysis
September 28, 2023 | finance.yahoo.com
UPDATE 2-PTC Therapeutics announces job cuts to lower annual operating expenses
September 25, 2023 | finance.yahoo.com
PTC Therapeutics (PTCT) Lost 16% in Q2
September 20, 2023 | finance.yahoo.com
PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?
September 19, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Werewolf Therapeutics (HOWL)
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
September 18, 2023 | msn.com
Citigroup Downgrades PTC Therapeutics (PTCT)
September 15, 2023 | markets.businessinsider.com
Goldman Sachs Keeps Their Sell Rating on PTC Therapeutics (PTCT)
September 15, 2023 | finance.yahoo.com
Biotech Crashes 30% After European Regulators Yank Approval For Muscle Disease Drug
September 15, 2023 | benzinga.com
PTC Therapeutics, Planet Fitness, Kemper And Other Big Stocks Moving Lower On Friday
September 15, 2023 | proactiveinvestors.com
PTC Therapeutics slumps on European snub for DMD drug
September 15, 2023 | finance.yahoo.com
Biotech Crashes 28% After European Regulators Yank Approval For Muscle Disease Drug
September 15, 2023 | stockhouse.com
CHMP Delivers Opinion on Translarna(TM) for Conversion to Full Authorization
September 15, 2023 | markets.businessinsider.com
PTC's Translarna Gets CHMP's Negative Opinion For Conversion To Full Marketing Authorization
September 15, 2023 | marketwatch.com
PTC Therapeutics: CHMP Recommends Against Full Translarna Approval >PTCT
September 15, 2023 | finance.yahoo.com
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
September 7, 2023 | finance.yahoo.com
Australian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy
August 28, 2023 | finance.yahoo.com
PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
August 17, 2023 | msn.com
Truist Securities Reiterates PTC Therapeutics (PTCT) Buy Recommendation
August 5, 2023 | finanznachrichten.de
PTC Therapeutics, Inc.: PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
August 5, 2023 | msn.com
Morgan Stanley Reiterates PTC Therapeutics (PTCT) Equal-Weight Recommendation
August 4, 2023 | finance.yahoo.com
PTC Therapeutics (PTCT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
August 3, 2023 | finance.yahoo.com
PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates
August 3, 2023 | finance.yahoo.com
PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
See More Headlines
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTCT Company Calendar

Last Earnings
8/03/2023
Today
10/02/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTCT
CUSIP
N/A
CIK
1070081
Web
www.ptcbio.com
Phone
(908) 222-7000
Fax
908-222-7231
Employees
1,410
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$39.57
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+76.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
13 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($8.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-559,020,000.00
Net Margins
-75.49%
Pretax Margin
-84.20%
Return on Equity
N/A
Return on Assets
-39.69%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.24
Quick Ratio
1.17

Sales & Book Value

Annual Sales
$698.80 million
Price / Sales
2.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.76) per share
Price / Book
-4.71

Miscellaneous

Outstanding Shares
75,350,000
Free Float
71,352,000
Market Cap
$1.69 billion
Optionable
Optionable
Beta
0.37
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Matthew B. Klein F.A.C.S. (Age 51)
    FACS, M.D., M.S., MS, CEO & Director
    Comp: $995.4k
  • Dr. Stuart W. Peltz Ph.D. (Age 63)
    Co-Founder, Sr. Consultant & Member of Scientific Advisory Board
    Comp: $1.54M
  • Dr. Allan Steven Jacobson Ph.D.Dr. Allan Steven Jacobson Ph.D. (Age 77)
    Co-Founder, Chairman of Scientific Advisory Board & Independent Director
    Comp: $145k
  • Dr. Neil Almstead Ph.D. (Age 56)
    Chief Technical Operations Officer
    Comp: $829.97k
  • Mr. Eric PauwelsMr. Eric Pauwels (Age 62)
    Chief Bus. Officer
    Comp: $847.67k
  • Mr. Pierre Gravier (Age 38)
    Chief Financial Officer
  • Ms. Christine Utter (Age 45)
    Sr. VP, Chief Accounting Officer & Head of People Services
  • Ms. Ellen Welch Ph.D.
    Chief Scientific Officer
  • Alex Kane
    Investor Relations Officer
  • Mr. Mark Elliott BouldingMr. Mark Elliott Boulding (Age 62)
    Exec. VP & Chief Legal Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PTCT Stock - Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last twelve months. There are currently 3 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares.
View PTCT analyst ratings or view top-rated stocks.

What is PTC Therapeutics' stock price forecast for 2023?

13 equities research analysts have issued 12 month price objectives for PTC Therapeutics' stock. Their PTCT share price forecasts range from $22.00 to $73.00. On average, they expect the company's share price to reach $39.57 in the next twelve months. This suggests a possible upside of 76.6% from the stock's current price.
View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts.

How have PTCT shares performed in 2023?

PTC Therapeutics' stock was trading at $38.17 on January 1st, 2023. Since then, PTCT stock has decreased by 41.3% and is now trading at $22.41.
View the best growth stocks for 2023 here.

When is PTC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our PTCT earnings forecast.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($2.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.58) by $1.08. The biopharmaceutical company earned $213.80 million during the quarter, compared to analysts' expectations of $206.99 million. The business's revenue was up 29.2% compared to the same quarter last year. During the same quarter last year, the business posted ($2.13) earnings per share.

What ETFs hold PTC Therapeutics' stock?

ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Motley Fool Small-Cap Growth ETF (TMFS), MFAM Small-Cap Growth ETF (MFMS), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Franklin Genomic Advancements ETF (HELX) and SPDR S&P Biotech ETF (XBI).

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics updated its FY 2023 earnings guidance on Wednesday, July, 19th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $940.00M-$1.00 billion, compared to the consensus revenue estimate of $961.42 million.

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $22.41.

How much money does PTC Therapeutics make?

PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $1.69 billion and generates $698.80 million in revenue each year. The biopharmaceutical company earns $-559,020,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis.

How many employees does PTC Therapeutics have?

The company employs 1,410 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231.

This page (NASDAQ:PTCT) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -